Sublingual allergy tablet launches in Canada; Elixir demonstrates new stent;

> ALK's ragweed sublingual allergy immunotherapy tablet, licensed to Merck ($MRK), just launched in Canada. Release

> Elixir Medical successfully demonstrated its DESolve 100 bioresorbable stent at the EuroPCR conference in Paris. Release

> Stanford researchers are developing small implants to be placed deep inside the body. These machines could someday replace pain medications, the scientists say. Story